

# Cinacalcet Hydrochloride (Sensipar) in Hemodialysis Patients on Active Vitamin D Derivatives with Controlled PTH and Elevated Calcium × Phosphate

Glenn M. Chertow,\* Samuel Blumenthal,<sup>†</sup> Stewart Turner,<sup>‡</sup> Michael Roppolo,<sup>§</sup> Leonard Stern,<sup>||</sup> Eric M. Chi,<sup>‡</sup> and John Reed;<sup>¶</sup> on behalf of the CONTROL Investigators

\*Departments of Medicine, Epidemiology and Biostatistics, University of California, San Francisco, School of Medicine, San Francisco, California; <sup>†</sup>Centre Point RCG Dialysis Center, West Allis, Wisconsin; <sup>‡</sup>Amgen, Inc., Thousand Oaks, California; <sup>§</sup>Renal Associates, Baton Rouge, Louisiana; <sup>||</sup>Columbia University, New York, New York; and <sup>¶</sup>Nephrology Associates PC, Columbus, Mississippi

Active vitamin D derivatives attenuate the severity of secondary hyperparathyroidism but often increase serum calcium (Ca) and phosphorus (P) as a result of enhanced intestinal absorption. The calcimimetic cinacalcet HCl lowers parathyroid hormone (PTH) and tends to decrease Ca × P. A 16-wk, open-label clinical trial was conducted in adult hemodialysis patients who had controlled PTH (biointact PTH [biPTH] 80 to 160 pg/ml) and elevated Ca × P (>55 mg<sup>2</sup>/dl<sup>2</sup>) and were receiving paricalcitol >6 μg/wk (or an equipotent dose of an alternative active vitamin D derivative). At the start of the study, active vitamin D derivatives were decreased to a mean equivalent dose of paricalcitol 6 μg/wk, and cinacalcet was titrated from 30 mg/d to a maximum possible dose of 180 mg/d. Of the 72 study patients, 53 (74%) completed 8 wk of dose titration with cinacalcet. In response to cinacalcet, the following mean percentage changes were observed: biPTH, -1.8%; Ca, -9.7% (*P* < 0.0001), phosphorus, -11.1% (*P* < 0.0001), and Ca × P, -20.1% (*P* < 0.0001). At the end of the study, approximate Kidney Disease Outcomes Quality Initiative targets for biPTH (≤160 pg/ml) were achieved in 85% (45 of 53) of patients and for Ca × P (≤55 mg<sup>2</sup>/dl<sup>2</sup>) in 72% (38 of 53) of patients. Concurrent achievement of both targets occurred in 47% (25 of 53) of patients. In this open-label clinical trial, hemodialysis patients who had controlled PTH but elevated Ca × P and were taking moderate- to high-dose active vitamin D derivatives achieved improved control of mineral metabolism with a combination of low-dose active vitamin D derivatives and cinacalcet. The long-term effects of this treatment regimen on clinical outcomes should be tested prospectively.

*Clin J Am Soc Nephrol* 1: 305–312, 2006. doi: 10.2215/CJN.00870805

Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD). Among patients who receive dialysis, SHPT often manifests as elevations in parathyroid hormone (PTH), serum calcium (Ca), and phosphorus (P). Elevations in these parameters of mineral metabolism have been associated with increased morbidity and mortality in multiple observational cohorts (1–3). Conventional management of SHPT includes the provision of active vitamin D derivatives and phosphate binders (Ca and non-Ca-based). Although active vitamin D derivatives are effective in reducing PTH levels, their use may exacerbate hypercalcemia and hyperphosphatemia as a result of enhanced intestinal Ca and P absorption (4). Therefore, despite the use of phosphate binders and active vitamin D derivatives, the majority of hemodialysis patients fail to achieve all four targets (PTH, Ca, P, and the Ca-P product [Ca × P]) recommended by the National Kidney Foun-

ation Kidney Disease Outcomes Quality Initiative (K/DOQI) clinical practice guidelines (5,6).

Calcimimetics bind to the Ca-sensing receptor, a G protein-coupled receptor that is present on the parathyroid gland (7). The calcimimetics, such as cinacalcet HCl, allosterically modulate the Ca-sensing receptor, increasing its sensitivity to extracellular Ca and thereby decreasing PTH synthesis and secretion from the parathyroid gland (8,9). Cinacalcet reduces PTH with simultaneous decreases in both serum concentrations of Ca and P (10,11). Cinacalcet in combination with low-dose active vitamin D derivatives enabled simultaneous achievement of the K/DOQI treatment goals in dialysis patients with elevated PTH and Ca × P levels (12). Because active vitamin D derivatives can increase Ca × P levels, the objective of this 16-wk study was to evaluate whether a treatment approach that included cinacalcet with low-dose active vitamin D derivatives enhanced the combined achievement of K/DOQI PTH and Ca × P targets in patients with controlled PTH and elevated Ca × P.

## Materials and Methods

### Study Design

This open-label clinical trial consisted of a 30-d screening phase, an 8-wk dose-titration phase, and an 8-wk assessment phase. Study visits

Received August 29, 2005. Accepted December 16, 2005.

Published online ahead of print. Publication date available at [www.cjasn.org](http://www.cjasn.org).

**Address correspondence to:** Dr. Glenn M. Chertow, Department of Medicine Research, UCSF Laurel Heights, Suite 430, 3333 California Street, San Francisco, CA 94118. Phone: 415-476-2173; Fax: 415-476-9531; E-mail: [chertowg@medicine.ucsf.edu](mailto:chertowg@medicine.ucsf.edu)

occurred at weekly intervals. Adults who were  $\geq 18$  yr of age and on maintenance hemodialysis thrice weekly for at least 3 mo were included in the study when two serum samples from the screening phase yielded a mean bioactive PTH (biPTH) between 80 and 160 pg/ml (approximately equivalent to intact PTH between 150 and 300 pg/ml), a mean  $\text{Ca} \times \text{P} > 55 \text{ mg}^2/\text{dl}^2$ , and a mean albumin-corrected serum Ca concentration  $\geq 8.4 \text{ mg/dl}$ . All patients were required to have received intravenous active vitamin D derivatives (doses of paricalcitol  $> 6 \mu\text{g}$ , doxercalciferol  $> 3 \mu\text{g}$ , or calcitriol  $> 1.5 \mu\text{g/wk}$ ) during the 30 d before study treatment. Exclusion criteria were pregnancy or nursing, use of inhibitors of cytochrome P450 (CYP3A4 (e.g., ketoconazole, itraconazole, erythromycin) or inducers of CYP3A4 (e.g., rifampin, St. John's Wort) within 21 d of study start, use of medications that are metabolized predominantly by CYP2D6 (e.g., flecainide, vinblastine, thioridazine, most tricyclic antidepressants) within 21 d of study start, myocardial infarction or parathyroidectomy within 3 mo, or any unstable medical condition. The study was conducted in accordance with the principles originating in the Declaration of Helsinki. The protocol and informed consent form were approved by the appropriate Independent Ethics Committee/Institutional Review Board, and written informed consent was obtained from all patients.

### Intervention (Drug Titrations)

On day 1 of the dose-titration phase, the active vitamin D derivative dose was decreased to low doses that are considered to be approximately physiologic (equivalent to paricalcitol  $2 \mu\text{g}$ , doxercalciferol  $1 \mu\text{g}$ , or calcitriol  $0.5 \mu\text{g}$  per dialysis session), and oral cinacalcet was initiated at  $30 \text{ mg/d}$ . The dose of cinacalcet could be increased every 2 wk sequentially to 60, 90, 120, and  $180 \text{ mg/d}$  when the biPTH was  $> 160 \text{ pg/ml}$  or between 80 and  $160 \text{ pg/ml}$  with  $\text{Ca} \times \text{P} > 55 \text{ mg}^2/\text{dl}^2$ . The dose of cinacalcet was not titrated further when the maximum dose had been reached, the serum Ca was  $< 8.4 \text{ mg/dl}$ , or an adverse event precluded a dose increase. The active vitamin D derivative dose could be increased when the patient had a serum Ca level  $< 8.4 \text{ mg/dl}$  or exhibited symptoms of hypocalcemia. The active vitamin D derivative dose could also be increased when biPTH was  $> 270 \text{ pg/ml}$  and  $\text{Ca} \times \text{P}$  was  $< 70 \text{ mg}^2/\text{dl}^2$  and cinacalcet could not be titrated further. The active vitamin D derivative dose could be decreased when two consecutive biPTH concentrations were  $< 80 \text{ pg/ml}$ . The doses of Ca-based and other phosphate binders could be adjusted throughout the study and could be increased when the serum Ca was  $< 8.4 \text{ mg/dl}$  or the patient had symptoms of hypocalcemia. The dose of cinacalcet could be decreased when the biPTH level was  $< 80 \text{ pg/ml}$  and active vitamin D derivative therapy had already been discontinued. When the biPTH dropped below  $80 \text{ pg/ml}$  on cinacalcet  $30 \text{ mg/d}$ , the dose could be reduced to  $30 \text{ mg}$  on alternate days.

### Efficacy and Safety Measures

Laboratory biochemical values (biPTH, serum Ca and serum P,  $\text{Ca} \times \text{P}$ ) were determined from blood samples that were collected before dialysis and the daily dose of cinacalcet at study visits at weeks 1, 3, 5, 7, 9, 11, 13, 15, and 16. The Nichols Advantage Bio-Intact PTH<sub>(1-84)</sub> immunometric assay (Nichols Institute Diagnostics, San Clemente, CA) was used by the central laboratory to measure biPTH. A strong correlation between the results of intact PTH and biPTH assays has been demonstrated (13), suggesting that the biPTH assay can be used to examine the attainment of K/DOQI or other clinical practice guideline targets.

The doses of active vitamin D derivatives and phosphate binders were recorded at each visit. Adverse events were collected from spon-

taneous reports and in response to nondirected questioning at each study visit.

### Statistical Analyses

The safety population included all patients who received at least one dose of cinacalcet. The efficacy population consisted of patients with at least one efficacy measurement during the assessment phase. The primary efficacy end points were mean proportion of patients with biPTH  $\leq 160 \text{ pg/ml}$  (approximately equal to iPTH  $\leq 300 \text{ pg/ml}$ ) and mean  $\text{Ca} \times \text{P} \leq 55 \text{ mg}^2/\text{dl}^2$  during the assessment phase and the absolute values and percentage changes from baseline for biPTH, serum Ca (corrected), serum P, and  $\text{Ca} \times \text{P}$ . Differences in biochemical parameter values at baseline and during the assessment phase were analyzed using paired *t* test. Secondary efficacy end points included combined achievement of the K/DOQI goals for biPTH and  $\text{Ca} \times \text{P}$ ; mean doses and changes in dose from baseline for active vitamin D derivatives and phosphate binders; and safety assessments, including all adverse events and the incidence of serum Ca concentrations  $< 8.4$  or  $< 7.5 \text{ mg/dl}$ .

## Results

### Study Population

The study was conducted from September 30, 2003, to June 30, 2004. Of the 72 patients who were enrolled and received study drug, 53 (74%) entered the 8-wk efficacy assessment phase and 39 (54%) completed the 16-wk study. The mean age of patients who entered the study was 57 yr; 45 (63%) patients were male and 38 (53%) were black (Table 1). All patients were receiving active vitamin D derivatives at baseline, in accordance with the study design.

Four (6%) patients discontinued because of adverse events. Overall, the most common additional reasons for early discontinuation were ineligibility for study inclusion on the basis of screening laboratory values ( $n = 11$ ; 15%), administrative decision ( $n = 5$ ; 7%), and withdrawal of consent ( $n = 4$ ; 6%). Baseline characteristics for patients who entered the assessment phase ( $n = 53$ ) were similar to the overall study population ( $n = 72$ ; Table 1).

### Effects of Cinacalcet on Biochemical End Points

Among the 53 patients who entered the assessment phase, baseline mean  $\pm$  SD concentration of biPTH was  $117.3 \pm 32 \text{ pg/ml}$  (Table 1). Forty-eight (91%) patients had a biPTH concentration  $\leq 160 \text{ pg/ml}$  at baseline, and 45 (85%) patients maintained this control during cinacalcet therapy (Figure 1). Because eligibility was determined in the screening phase before baseline, not all patients had a baseline mean biPTH  $< 160 \text{ pg/ml}$ . Mean biPTH remained within the K/DOQI target range (80 to  $160 \text{ pg/ml}$ ) throughout the study (Figure 2A). Only one patient had an active vitamin D derivative dose increase as a result of failure to control the biPTH with cinacalcet.

The mean  $\pm$  SD serum Ca concentration at baseline was  $9.7 \pm 0.7 \text{ mg/dl}$  (Table 1). Treatment with cinacalcet significantly reduced mean serum Ca (Figure 3) to  $8.8 \text{ mg/dl}$  during the assessment phase ( $P < 0.0001$  versus baseline). The mean serum Ca was within the K/DOQI target range after 1 wk of cinacalcet treatment and remained within range throughout the study (Figure 2B).

Table 1. Baseline demographics and clinical characteristics<sup>a</sup>

Characteristic	Safety Population (n = 72)	Assessment Phase Population (n = 53)
Gender (n [%])		
male	45 (63)	33 (62)
female	27 (38)	20 (38)
Race (n [%])		
black	38 (53)	25 (47)
white	30 (42)	25 (47)
other	4 (6)	3 (6)
Age (yr [mean ± SD])	56.9 ± 11.8	57.8 ± 12.8
Active vitamin D derivative use (n [%])	72 (100)	53 (100)
Phosphate binder use (n [%])	71 (99)	53 (100)
biPTH (pg/ml [mean ± SD])	118.9 ± 32.5	117.3 ± 32.0
Ca × P (mg <sup>2</sup> /dl <sup>2</sup> [mean ± SD])	59.6 ± 14.6	63.8 ± 10.8
Serum calcium (mg/dl [mean ± SD])	9.7 ± 0.7	9.7 ± 0.7
Serum phosphorus (mg/dl [mean ± SD])	6.2 ± 1.5	6.6 ± 1.2

<sup>a</sup>biPTH, biointact parathyroid hormone; Ca × P, calcium-phosphorus product. Dialysate calcium concentration 2.5 mEq/L was used.




Figure 1. Achievement of Kidney Disease Outcomes Quality Initiative (KDOQI) goals for biointact parathyroid hormone (biPTH) and calcium-phosphorus product (Ca × P) among patients who reached the assessment phase (n = 53). The primary efficacy end points of the study were mean biPTH of ≤160 pg/ml and Ca × P of ≤55 mg<sup>2</sup>/dl<sup>2</sup>. A secondary efficacy end point was concurrent achievement of the goals for both biPTH and Ca × P.

The mean ± SD serum P concentration at baseline was 6.6 ± 1.2 mg/dl (Table 1). Treatment with cinacalcet significantly reduced mean serum P to 5.7 mg/dl (P < 0.0001 versus baseline; Figure 3). Mean serum P concentrations were reduced to within the K/DOQI target range (3.5 to 5.5 mg/dl) by week 13 of the assessment phase (Figure 2C).

The mean ± SD Ca × P at baseline was 63.8 ± 10.8 mg<sup>2</sup>/dl<sup>2</sup> (Table 1). Cinacalcet treatment significantly reduced mean

Ca × P to 50.0 mg<sup>2</sup>/dl<sup>2</sup> (P < 0.0001 versus baseline; Figure 3). Improvement in mean Ca × P was rapid and sustained, occurring within the first week of cinacalcet treatment and lasting throughout the study (Figure 2D). In line with the sustained decrease in Ca × P, treatment with cinacalcet increased the percentage of patients who achieved the K/DOQI Ca × P goal of ≤55 mg<sup>2</sup>/dl<sup>2</sup> from baseline to the assessment phase (21 versus 72%; P < 0.0001; Figure 1). As was observed with biPTH, eligibility was determined in the screening phase before baseline, and accordingly, 11 patients had a baseline mean Ca × P < 55 mg<sup>2</sup>/dl<sup>2</sup>.

Finally, a key aspect of this study was to determine whether administration of cinacalcet in combination with low-dose active vitamin D derivatives could maintain control of biPTH and provide improved Ca × P control compared with conventional moderate- to high-dose active vitamin D derivative therapy. Indeed, 47% (n = 25) of patients jointly achieved the target levels for both biPTH and Ca × P (Figure 1).

#### Medication Use

All patients were receiving active vitamin D derivatives at baseline. The mean ± SD equivalent paricalcitol dose at baseline for the 53 patients who subsequently reached the assessment phase was 14.1 ± 7.8 μg/wk (Table 2). By the assessment phase, 21% of patients had stopped taking active vitamin D derivatives completely. For the remainder, the mean dose was decreased by approximately 49% to 6.9 μg/wk (Table 2). All patients who reached the assessment phase were receiving phosphate binders at the start of the study. The proportion of patients who were receiving sevelamer was similar at baseline and during the assessment phase of the study (59 versus 57%). The mean sevelamer dose decreased nonsignificantly from 9036 to 8250 mg/d (Table 2). Use of Ca-based phosphate binders increased from baseline to the assessment phase, both in terms of the percentage of patients who were taking the binders (from




Figure 2. Mean  $\pm$  SEM laboratory values by study week. biPTH (A), serum Ca (B), serum P (C), and Ca  $\times$  P (D).

62 to 79%) and significantly with respect to the mean dose (from 1435 to 1847 mg/d of elemental Ca; Table 2). All patients started the study on 30 mg once daily of cinacalcet. The mean  $\pm$  SD dose at week 16 (end of study) was  $55 \pm 29$  mg/d.

#### Safety

During the course of the study, 74% (53 of 72) of enrolled patients reported adverse events, which were predominately




Figure 3. Mean percentage change in biochemical end points from baseline during cinacalcet therapy. \*Objective was to stay in range at approximate baseline level.

mild to moderate in severity and similar to those previously reported (10,11). The most commonly reported adverse events included nausea ( $n = 10$ ; 14%), vomiting ( $n = 10$ ; 14%), and diarrhea ( $n = 9$ ; 13%; Table 3). The level of biPTH fell below 80 pg/ml for 53 (74%) patients but returned to the target range in 42 of these patients. Of the 11 patients whose biPTH levels did not return to  $>80$  pg/ml, six discontinued the study after the laboratory test had been obtained (and before a follow-up laboratory test), and one patient experienced the low biPTH value at the end of the study (week 15). Four patients had sustained low biPTH concentrations throughout the study. Overall, 17 (24%) patients had two consecutive serum Ca levels  $<8.4$  mg/dl, and one (1%) patient had two consecutive values  $<7.5$  mg/dl. No patient discontinued cinacalcet therapy as a result of hypocalcemia. One patient with a history of seizure disorder experienced generalized seizure approximately 2 mo after initiating cinacalcet therapy; the event was considered to be unrelated to cinacalcet treatment by the investigator. Four patients died during the study (angina pectoris, foot infection, respiratory arrest, and unexplained death); none of the deaths was considered to be related to cinacalcet.

#### Discussion

In this 16-wk, open-label clinical trial, we enrolled patients who were on hemodialysis and receiving active vitamin D derivatives and controlled biPTH and elevated Ca  $\times$  P levels. We evaluated the effect of a treatment approach that incorporated cinacalcet plus low-dose active vitamin D derivatives on control of SHPT and attainment of K/DOQI targets. The introduction of cinacalcet maintained control of biPTH and, in addition, significantly improved control of Ca  $\times$  P, resulting in an increase in the proportion of patients who simultaneously achieved the biPTH and Ca  $\times$  P target levels (17 to 47% during the course of the study). During the study, 20% of patients discontinued active vitamin D derivatives completely, and the average dose for the remaining patients fell by 49%. In addition to demonstrated efficacy on biochemical outcomes, cinacalcet was well tolerated. As in earlier studies (10,11), gastrointestinal symptoms were the most commonly observed side effects but generally were mild in intensity. No patient experienced symptoms of hypocalcemia, and none was withdrawn as a result of hypocalcemia.

Table 2. Use of concomitant medications for SHPT at baseline and during the assessment phase in the efficacy population<sup>a</sup>

	Baseline (n = 53)	Assessment Phase (n = 53)
Active vitamin D derivative use		
received active vitamin D derivative (n [%])	53 (100)	42 (79)
paricalcitol dose equivalents <sup>b</sup> (μg/wk [mean ± SD])	14.1 ± 7.8	6.9 ± 4.6 <sup>c</sup>
Phosphate binder use	53 (100)	52 (98)
Sevelamer use		
received sevelamer (n [%])	31 (59)	30 (57)
sevelamer dose (mg/d [mean ± SD])	9036 ± 5033	8250 ± 4980 <sup>d</sup>
Ca-based phosphate binder use		
received a Ca-based phosphate binder (n [%])	33 (62)	42 (79)
total elemental Ca intake (mg/d [mean ± SD])	1435 ± 1030	1847 ± 1307 <sup>e</sup>

<sup>a</sup>SHPT, secondary hyperparathyroidism.

<sup>b</sup>2 μg paricalcitol = 1 μg doxercalciferol = 0.5 μg calcitriol.

<sup>c</sup>P < 0.0001 among 42 patients on active vitamin D derivatives at baseline and in assessment phase.

<sup>d</sup>P = 0.13 among 28 patients who were on sevelamer at baseline and in assessment phase.

<sup>e</sup>P = 0.0013 among 32 patients on Ca-based phosphate binder at baseline and in assessment phase.

Table 3. Adverse events in >5% of patients

Event	n (%; N = 72)
Nausea	10 (14)
Vomiting	10 (14)
Diarrhea	9 (13)
Arthralgia	6 (8)
Graft thrombosis	6 (8)
Upper respiratory tract infection	5 (7)
Constipation	4 (6)
Hypotension	4 (6)
Rigors	4 (6)

SHPT generally is associated with abnormally high rates of bone resorption and is often accompanied by pain and fractures (14–16). Extraskeletal manifestations of the disease include vascular calcification, hypertension, anemia, pruritus, and sexual dysfunction (17–25). Analyses of data from large hemodialysis cohorts (1–3) have demonstrated significant relations among elevated PTH, Ca, and P and mortality and morbidity. Block *et al.* (3) showed that PTH concentrations >600 pg/ml were associated with an increase in the risk for death compared with PTH concentrations <600 pg/ml; higher PTH was also associated with higher risks for cardiovascular disease and fracture. In the same analysis, hyperphosphatemia was strongly associated with mortality, cardiovascular disease, and fracture; hypercalcemia was also associated with mortality (3). The K/DOQI treatment guidelines provide recommended target levels for PTH (150 to 300 pg/ml), serum Ca (8.4 to 9.5 mg/dl), P (3.5 to 5.5 mg/dl), and Ca × P (<55 mg<sup>2</sup>/dl<sup>2</sup>) (6). Observational studies have shown that being “in range” is associated with enhanced survival (3,5). Although treatment of SHPT is often aimed at the achievement of these goals, to date, no interventional studies have demonstrated that achievement of

K/DOQI targets directly improves clinical outcomes. Randomized trials to compare alternative Ca or P targets have not been conducted.

Active vitamin D derivatives are commonly used for the treatment of SHPT (26). In addition to their effects on the parathyroid gland, potential benefits on muscle and immune function have been suggested (27–33). Treating SHPT with active vitamin D derivatives necessitates balancing its effect on PTH reduction with its effects on Ca and P absorption (leading to hypercalcemia and hyperphosphatemia). Hence, achievement of all K/DOQI bone metabolism and disease targets simultaneously is challenging (5). Our study has addressed a common clinical dilemma: Determining optimal management of mineral metabolism when PTH concentrations can be controlled with active vitamin D derivatives. The study has demonstrated the feasibility and the efficacy of combination therapy with cinacalcet and low-dose active vitamin D derivatives. Dual control of PTH and Ca × P, according to K/DOQI recommendations, can be achieved in 47% of patients with this strategy. Because these patients were previously being treated with vitamin D and phosphate binders, these data suggest that use of cinacalcet may lead to a greater percentage of patients' achieving K/DOQI targets. It is interesting that 20% of patients in the study discontinued active vitamin D derivatives, yet the overall population remained well managed with cinacalcet and phosphate binders alone.

Clinical trials using active vitamin D derivatives have included primarily small placebo-controlled or active vitamin D derivative comparison studies that evaluated effects on biochemical end points (34–38) or bone histomorphology and other surrogate markers (39–42). In an observational study that included >30,000 hemodialysis patients, Teng *et al.* (43) showed a 20% reduction in mortality among patients who were treated with active vitamin D derivatives compared with those who were not treated; subgroup analyses showed a benefit of active

vitamin D derivatives even among patients with high serum P and low PTH concentrations. Although these data suggest a benefit of active vitamin D derivatives on mortality, the results could be explained by residual confounding. In a similar retrospective analysis, Young *et al.* (2) did not observe a relation between activated vitamin D derivative use and mortality. Henley *et al.* (44) recently demonstrated progressive aortic calcification in rats that had SHPT and were treated with calcitriol, whereas vehicle- and cinacalcet-treated rats had no significant calcification, although extremely high doses of calcitriol were used (100 ng, corresponding to 0.25 to 0.28  $\mu\text{g}/\text{kg}$  body wt). In humans, broad clinical experience has demonstrated increased Ca and P levels with vitamin D therapy (34,45–47). In a pooled *post hoc* analysis of prospective, randomized studies, a significant reduction in hospitalization for cardiovascular disease and fracture and an improvement in self-reported physical function were observed among patients who were randomly assigned to cinacalcet *versus* placebo when added to conventional therapy (48). It will be important to evaluate whether a combination of cinacalcet and low-dose active vitamin D derivatives might provide greater clinical benefit. For addressing this question definitively, prospective, long-term clinical trials to evaluate the effects of active vitamin D derivatives and cinacalcet on mortality, cardiovascular events, fracture, and other outcomes are required.

The dose of Ca-based phosphate binders that were prescribed after starting cinacalcet was increased. Oral Ca from phosphate binders has been associated with vascular calcification (20,21), and, compared with sevelamer, doses of oral Ca in the range provided here resulted in more rapid progression of vascular calcification (49,50) and a reduction in bone attenuation (51) in hemodialysis patients. Although the provision of Ca-based phosphate binders may normalize serum Ca after cinacalcet therapy, the net benefits of serum Ca correction *versus* the potential adverse effects of Ca loading are unknown. Although preclinical studies have shown that calcimimetics are not associated with vascular calcification (44), the effect of treatment with cinacalcet and Ca-based phosphate binders warrants further investigation.

Our study has some limitations. The sample size was small, and the study was open label. However, the study results were consistent with the biochemical effects seen in previous placebo-controlled, randomized trials (10,11). Different active vitamin D derivatives may exert varying effects on the absorption of Ca and P from the intestinal tract. Moreover, the use of Ca-containing phosphate binders may increase serum Ca. Because the protocol did not mandate specific active vitamin D derivatives or phosphate binders, differences in co-interventions may have confounded the results. However, the clinical dilemma addressed by this study is common, and the results can be used to inform clinical practice.

## Conclusion

This study has demonstrated that combined therapy with cinacalcet and low-dose active vitamin D derivatives improves control of PTH and Ca  $\times$  P in hemodialysis patients with SHPT and elevated Ca  $\times$  P and increases the likelihood of achieving

K/DOQI targets. The long-term effects of this therapeutic approach on clinical outcomes should be tested prospectively.

## Acknowledgments

This study was supported by a grant from Amgen, Inc.

A portion of these data were presented at the American Society of Nephrology meeting in St. Louis, Missouri, October 27 to November 1, 2004.

The CONTROL investigators included Suhail Ahmad, MD, Joseph Anzalone, MD, Jose Arruda, MD, Marrell Avarm, MD, Habib Azad, MD, Kevin Barber, MD, Mario Belledonne, MD, Samuel Blumenthal, MD, David Bushinsky, MD, Jose Cangiano, MD, Chaim Charytan, MD, Glenn Chertow, MD, Michel Chonchol, MD, Roderick Clark, MD, Jack Coburn, MD, Maria Coco, MD, Loren Cohen, MD, Michael Cook, MD, Norman Coplon, MD, Paul Dykes, MD, George Fadda, MD, Mark Farber, MD, Esther Gonzalez, MD, Cern Harmanci, MD, Mark Kaplan, MD, Charles Kaupke, MD, Gerald Keightly, MD, Romesh Kohli, MD, Nelson Kopyt, MD, Manjula Kurella, MD, Marc Leiserowitz, MD, Martin Lunde, MD, Robert Lynn, MD, John MacLaurin, MD, Dwight Makoff, MD, Robert McCary, MD, Ravindra Mehta, MD, Beckie Michael, DO, Steven Mischel, MD, Jesus Navarro, MD, Tuan Ngo, MD, Donovan Polack, MD, John Reed, MD, Michael Rokaw, MD, Michael Roppolo, MD, Melvin Seek, MD, Mohamed Sekkarie, MD, Warren Shapiro, MD, Jeffery Silberzweig, MD, David Simon, MD, Gary Singer, MD, Charles Smith, MD, Charles Spalding, MD, Stuart Sprague, MD, Marc Stegman, MD, Leonard Stern, MD, James Strom, MD, Jared Sugihara, MD, David Tharpe, MD, Kant Tucker, MD, Marc Weiner, MD, Thomas Wooldrige, MD, and Steven Zeig, MD.

We thank William W Stark, Jr, PhD, for assistance in the preparation of this manuscript.

## References

1. Slinin Y, Foley RN, Collins AJ: Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: The USRDS Waves 1, 3, and 4 Study. *J Am Soc Nephrol* 16: 1788–1793, 2005
2. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piersa L, Port FK: Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. *Kidney Int* 67: 1179–1187, 2005
3. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. *J Am Soc Nephrol* 15: 2208–2218, 2004
4. Walling MW: Intestinal Ca and phosphate transport: Differential responses to vitamin D3 metabolites. *Am J Physiol* 233: E488–E494, 1977
5. Young EW, Akiba T, Albert JM, McCarthy JT, Kerr PG, Mendelssohn DC, Jadoul M: Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Am J Kidney Dis* 44: 34–38, 2004
6. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. *Am J Kidney Dis* 42[Suppl]: S1–S201, 2003
7. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC: Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. *Nature* 366: 575–580, 1993

8. Levi R, Gaberman E, Silver J, Martin D, Naveh-Many T: The calcimimetic NPS R-568 decreases PTH gene expression in rats with secondary hyperparathyroidism due to experimental uremia [Abstract]. *Nephrol Dial Transplant* 20: V24, 2005
9. Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, Colloton M, Karbon W, Scherrer J, Shatzen E, Rishton G, Scully S, Qi M, Harris R, Lacey D, Martin D: Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. *J Pharmacol Exp Ther* 308: 627–635, 2004
10. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW: Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. *J Am Soc Nephrol* 16: 800–807, 2005
11. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. *N Engl J Med* 350: 1516–1525, 2004
12. Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, Drueke TB, Cunningham J, Sherrard DJ, McCary LC, Olson KA, Turner SA, Martin KJ: Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. *Kidney Int* 67: 760–771, 2005
13. Fujimori A, Sakai M, Yoshiya K, Shin J, Kim JI, Inaba Y, Miyamoto T, Inoue S, Fukagawa M: Bio-intact parathyroid hormone and intact parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism receiving intravenous calcitriol therapy. *Ther Apher Dial* 8: 474–479, 2004
14. Hruska KA, Teitelbaum SL: Renal osteodystrophy. *N Engl J Med* 333: 166–174, 1995
15. Pasiaka JL, Parsons LL: A prospective surgical outcome study assessing the impact of parathyroidectomy on symptoms in patients with secondary and tertiary hyperparathyroidism. *Surgery* 128: 531–539, 2000
16. Stracke S, Jehle PM, Sturm D, Schoenberg MH, Widmaier U, Beger HG, Keller F: Clinical course after total parathyroidectomy without autotransplantation in patients with end-stage renal failure. *Am J Kidney Dis* 33: 304–311, 1999
17. Abdelfatah AB, Motte G, Ducloux D, Chalopin JM: Determinants of mean arterial pressure and pulse pressure in chronic haemodialysis patients. *J Hum Hypertens* 15: 775–779, 2001
18. Bro S, Olgaard K: Effects of excess PTH on nonclassical target organs. *Am J Kidney Dis* 30: 606–620, 1997
19. Chou FF, Lee CH, Shu K, Yu TJ, Hsu KT, Sheen-Chen SM: Improvement of sexual function in male patients after parathyroidectomy for secondary hyperparathyroidism. *J Am Coll Surg* 193: 486–492, 2001
20. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. *N Engl J Med* 342: 1478–1483, 2000
21. Guerin AP, London GM, Marchais SJ, Metivier F: Arterial stiffening and vascular calcifications in end-stage renal disease. *Nephrol Dial Transplant* 15: 1014–1021, 2000
22. Lee CT, Chou FF, Chang HW, Hsu YH, Lee WC, Liao SC, Chen JB: Effects of parathyroidectomy on iron homeostasis and erythropoiesis in hemodialysis patients with severe hyperparathyroidism. *Blood Purif* 21: 369–375, 2003
23. Ribeiro S, Ramos A, Brandao A, Rebelo JR, Guerra A, Resina C, Vila-Lobos A, Carvalho F, Remedio F, Ribeiro F: Cardiac valve calcification in haemodialysis patients: Role of calcium-phosphate metabolism. *Nephrol Dial Transplant* 13: 2037–2040, 1998
24. Urena P, Eckardt KU, Sarfati E, Zingraff J, Zins B, Roullet JB, Roland E, Drueke T, Kurtz A: Serum erythropoietin and erythropoiesis in primary and secondary hyperparathyroidism: Effect of parathyroidectomy. *Nephron* 59: 384–393, 1991
25. Rao DS, Shih MS, Mohini R: Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. *N Engl J Med* 328: 171–175, 1993
26. USRDS 2004 Annual Data Report. *Am J Kidney Dis* 45: 8–280, 2005
27. Wanic-Kossowska M, Grzegorzewska A, Plotast H, Bombicki K: Does calcitriol therapy improve muscle function in uremic patients? *Perit Dial Int* 16[Suppl 1]: S305–S308, 1996
28. Tanaci N, Karakose H, Guvener N, Tutuncu NB, Colak T, Haberal M: Influence of 1,25-dihydroxyvitamin D3 as an immunomodulator in renal transplant recipients: A retrospective cohort study. *Transplant Proc* 35: 2885–2887, 2003
29. Hmama Z, Sendide K, Talal A, Garcia R, Dobos K, Reiner NE: Quantitative analysis of phagolysosome fusion in intact cells: Inhibition by mycobacterial lipoarabinomannan and rescue by an 1 $\alpha$ ,25-dihydroxyvitamin D3-phosphoinositide 3-kinase pathway. *J Cell Sci* 117: 2131–2140, 2004
30. van Halteren AG, Tysma OM, van Etten E, Mathieu C, Roep BO: 1 $\alpha$ ,25-Dihydroxyvitamin D3 or analogue treated dendritic cells modulate human autoreactive T cells via the selective induction of apoptosis. *J Autoimmun* 23: 233–239, 2004
31. Lyakh LA, Sanford M, Chekol S, Young HA, Roberts AB: TGF- $\beta$  and vitamin D3 utilize distinct pathways to suppress IL-12 production and modulate rapid differentiation of human monocytes into CD83+ dendritic cells. *J Immunol* 174: 2061–2070, 2005
32. Chen L, Cencioni MT, Angelini DF, Borsellino G, Battistini L, Brosnan CF: Transcriptional profiling of gamma delta T cells identifies a role for vitamin D in the immunoregulation of the V gamma 9V delta 2 response to phosphate-containing ligands. *J Immunol* 174: 6144–6152, 2005
33. Stefanovic V, Djordjevic V, Ivic M, Mitic-Zlatkovic M, Vlahovic P: Lymphocyte PC-1 activity in patients on maintenance haemodialysis treated with human erythropoietin and 1- $\alpha$ -D3. *Ann Clin Biochem* 42: 55–60, 2005
34. Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J, Arruda J, Lau A, Slatopolsky E: Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-Nor-1,25-dihydroxyvitamin D2. *Am J Kidney Dis* 32: S48–S54, 1998
35. Martin KJ, Gonzalez E, Lindberg JS, Taccetta C, Amdahl M, Malhotra K, Llach F: Paricalcitol dosing according to body weight or severity of hyperparathyroidism: A double-

- blind, multicenter, randomized study. *Am J Kidney Dis* 38: S57–S63, 2001
36. Koshikawa S, Akizawa T, Kurokawa K, Marumo F, Sakai O, Arakawa M, Morii H, Seino Y, Ogata E, Ohashi Y, Akiba T, Tsukamoto Y, Suzuki M: Clinical effect of intravenous calcitriol administration on secondary hyperparathyroidism. A double-blind study among 4 doses. *Nephron* 90: 413–423, 2002
  37. Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J: 19-Nor-1-alpha-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. *J Am Soc Nephrol* 9: 1427–1432, 1998
  38. Tan AU Jr, Levine BS, Mazess RB, Kylo DM, Bishop CW, Knutson JC, Kleinman KS, Coburn JW: Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. *Kidney Int* 51: 317–323, 1997
  39. Giannini S, D'Angelo A, Nobile M, Carraro G, Rigotti P, Silva-Netto F, Pavan S, Marchini F, Zaninotto M, Dalla Carbonare L, Sartori L, Crepaldi G: The effects of vitamin d receptor polymorphism on secondary hyperparathyroidism and bone density after renal transplantation. *J Bone Miner Res* 17: 1768–1773, 2002
  40. Parisi MS, Oliveri B, Somoza J, Mautalen C: Effect of doxercalciferol (1alpha-hydroxyvitamin D2) on PTH, bone turnover and bone mineral density in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy. *Clin Nephrol* 59: 471–474, 2003
  41. Baskin E, Ozen S, Karcaaltincaba M, Besbas N, Saatci U, Duzova A, Agras PI, Haliloglu M, Bakkaloglu A: Beneficial role of intravenous calcitriol on bone mineral density in children with severe secondary hyperparathyroidism. *Int Urol Nephrol* 36: 113–118, 2004
  42. Costa AF, dos Reis LM, Ribeiro MC, Moyses RM, Jorgetti V: Effects of calcitriol on parathyroid function and on bone remodelling in secondary hyperparathyroidism. *Nephrol Dial Transplant* 18: 743–749, 2003
  43. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R: Activated injectable vitamin D and hemodialysis survival: A historical cohort study. *J Am Soc Nephrol* 16: 1115–1125, 2005
  44. Henley C, Colloton M, Cattley RC, Shatzen E, Towler DA, Lacey D, Martin D: 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. *Nephrol Dial Transplant* 20: 1370–1377, 2005
  45. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. *N Engl J Med* 349: 446–456, 2003
  46. Llach F, Yudd M: Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. *Am J Kidney Dis* 38: S45–S50, 2001
  47. Gallieni M, Brancaccio D, Padovese P, Rolla D, Bedani P, Colantonio G, Bronzileri C, Bagni B, Tarolo G: Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol. *Kidney Int* 42: 1191–1198, 1992
  48. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM: Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. *Kidney Int* 68: 1793–1800, 2005
  49. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. *Kidney Int* 62: 245–252, 2002
  50. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P: Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. *Kidney Int* 68: 1815–1824, 2005
  51. Raggi P, James G, Burke SK, Bommer J, Chasan-Taber S, Holzer H, Braun J, Chertow GM: Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. *J Bone Miner Res* 20: 764–772, 2005

See related editorial, "Calcium, Calcimimetics and Clinical Outcomes," on pages 170–171.

Clinical use of the calcimimetic cinacalcet in hemodialysis (Chertow *et al.*) and transplant patients (Srinivas *et al.*) with the corresponding editorial by Block are featured in this month's *CJASN*. A study in experimental animals on another congener by Lopez *et al.* in this month's *JASN* (pages 795–804) shows a decrease in extrasosseous calcifications, even in calcitriol-treated animals.